PARP inhibitor biomarkers find significant utility in molecular diagnostic assays used in detecting cancers and directing targeted cancer therapies. These biomarkers play an important role in understanding the mechanism of action of PARP inhibitors employed in cancer treatment. PARP inhibitors target and inhibit poly ADP-ribose polymerase, an enzyme involved in DNA repair that when blocked, causes synthetic lethality in cancer cells defective in homologous recombination repair, like those with BRCA1 and BRCA2 mutations. Molecular diagnostic tools leveraging PARP biomarkers help oncologists select appropriate patient groups most likely to respond to PARP inhibitor therapies. The global PARP Inhibitor Biomarkers Market is estimated to be valued at US$ 5.62 billion in 2024 and is expected to exhibit a CAGR of 49% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The development of novel and sensitive molecular diagnostic assays incorporating PARP inhibitor biomarkers is one of the major trends fueling the growth of this market. Technological advancements enabling detection of subtle genetic alterations in tumor samples and liquid biopsies have expanded the clinical utility of PARP biomarkers. Sophisticated tools based on principles of PCR, NGS, fluorescence in situ hybridization and immunohistochemistry now allow comprehensive molecular profiling of tumors to identify those most responsive to PARP inhibition. This facilitates optimized clinical decision making and more personalized treatment approaches in oncology.
Segment Analysis
The global PARP Inhibitor Biomarkers market is dominated by the ovarian cancer sub-segment due to the growing prevalence of ovarian cancer across the world. Ovarian cancer accounted for more than 50% share of the overall PARP Inhibitor Biomarkers market in 2024. PARP inhibitors are gaining widespread acceptance for the treatment of ovarian cancer which is driving the growth of this sub-segment.
Key Takeaways
The global PARP Inhibitor Biomarkers Market is expected to witness high growth at a CAGR of 49% during the forecast period of 2024-2031.The market is projected to reach a size of US$ 5.62 Bn by 2024.
Regional analysis: North America currently dominates the global PARP Inhibitor Biomarkers market and is expected to maintain its leading position during the forecast period as well. The high growth in the region can be attributed to the growing prevalence of cancer and increasing adoption of targeted drug therapies for cancer treatment in the US and Canada. Moreover, presence of leading players in the region is also driving the market growth.
Key players operating in the PARP Inhibitor Biomarkers market are BASF SEChembond Chemicals LimitedGE Water and Process TechnologiesKurita Water Industries Ltd.Ion ExchangeKemira OyjAkzoNobel N.V.SolenisThermax Ltd.Veolia Water TechnologiesAccepta Advanced Environmental TechnologiesHubbard-Hall IncBeckart EnvironmentalEcolab Incorporated. These players are focusing on new product launches and strategic collaborations to strengthen their market position.
For more insights, read- https://www.insightprobing.com/parp-inhibitor-biomarkers-market-trends-size-and-share-analysis/
For more details on the report, Read- https://masstamilan.tv/signage-an-integral-part-of-marketing-strategy/
Comments
0 comment